IRIS UniCatt

Di Giambenedetto, Simona
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.367
EU - Europa 10.401
AS - Asia 9.391
SA - Sud America 1.988
AF - Africa 306
OC - Oceania 43
Continente sconosciuto - Info sul continente non disponibili 12
AN - Antartide 1
Totale 35.509
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.928
SG - Singapore 4.349
DE - Germania 2.568
CN - Cina 2.086
BR - Brasile 1.636
SE - Svezia 1.571
IT - Italia 1.302
FR - Francia 1.270
PL - Polonia 826
VN - Vietnam 806
UA - Ucraina 636
IE - Irlanda 477
GB - Regno Unito 467
IN - India 417
NL - Olanda 414
ID - Indonesia 312
FI - Finlandia 293
JP - Giappone 225
CA - Canada 224
HK - Hong Kong 195
RU - Federazione Russa 191
BD - Bangladesh 188
AR - Argentina 151
TR - Turchia 147
MX - Messico 120
IQ - Iraq 102
ZA - Sudafrica 86
PK - Pakistan 72
ES - Italia 65
BE - Belgio 63
AT - Austria 62
IR - Iran 57
SA - Arabia Saudita 51
KR - Corea 45
MA - Marocco 44
VE - Venezuela 39
EC - Ecuador 38
PH - Filippine 36
UZ - Uzbekistan 36
LT - Lituania 35
AU - Australia 34
CO - Colombia 33
KE - Kenya 31
EG - Egitto 30
CH - Svizzera 29
JO - Giordania 28
CL - Cile 26
TN - Tunisia 26
CI - Costa d'Avorio 25
PY - Paraguay 23
KZ - Kazakistan 22
MY - Malesia 22
AZ - Azerbaigian 20
JM - Giamaica 20
IL - Israele 19
AE - Emirati Arabi Uniti 17
PE - Perù 16
CZ - Repubblica Ceca 14
OM - Oman 14
NP - Nepal 13
TW - Taiwan 13
UY - Uruguay 13
CR - Costa Rica 12
LB - Libano 12
AL - Albania 11
BO - Bolivia 11
CM - Camerun 11
DZ - Algeria 11
GR - Grecia 11
HN - Honduras 11
PA - Panama 11
RO - Romania 11
NG - Nigeria 10
PT - Portogallo 10
TH - Thailandia 10
DO - Repubblica Dominicana 9
EU - Europa 9
MD - Moldavia 9
PS - Palestinian Territory 9
BH - Bahrain 8
ET - Etiopia 8
KG - Kirghizistan 8
NZ - Nuova Zelanda 8
BG - Bulgaria 7
LV - Lettonia 7
NI - Nicaragua 7
QA - Qatar 7
TT - Trinidad e Tobago 7
DK - Danimarca 6
LK - Sri Lanka 6
NO - Norvegia 6
RS - Serbia 6
BY - Bielorussia 5
CY - Cipro 5
HR - Croazia 5
LA - Repubblica Popolare Democratica del Laos 5
BA - Bosnia-Erzegovina 4
GE - Georgia 4
GT - Guatemala 4
HU - Ungheria 4
Totale 35.423
Salva come PNG Salva come JPEG
Città #
Singapore 2.245
Chandler 1.920
Ashburn 1.521
San Jose 1.248
Kraków 599
New York 568
Dublin 469
Jacksonville 421
Beijing 407
San Mateo 382
Amsterdam 381
Milan 313
Los Angeles 286
Jakarta 280
Lauterbourg 277
Ho Chi Minh City 271
Rome 231
Nanjing 227
Wilmington 221
Warsaw 206
Boston 204
Tokyo 198
Hanoi 196
Hefei 190
Ann Arbor 186
Houston 184
The Dalles 179
Hong Kong 166
Dearborn 164
Dallas 148
São Paulo 144
Frankfurt am Main 136
Princeton 127
Cattolica 126
Chicago 124
Lawrence 122
Nürnberg 110
Munich 108
Helsinki 107
Moscow 107
Woodbridge 107
Redwood City 104
Santa Clara 102
Nanchang 95
St Louis 95
Seattle 92
Orem 85
Marseille 83
Boardman 79
Buffalo 79
Redmond 75
Izmir 67
London 67
Montreal 65
Brussels 60
Lancaster 60
Nuremberg 60
Brooklyn 59
Fairfield 58
Bremen 55
Düsseldorf 55
Atlanta 54
Paris 54
Shenyang 52
Toronto 52
Mountain View 50
Rio de Janeiro 50
Johannesburg 49
Kent 47
Pune 47
Norwalk 45
Poplar 44
Changsha 43
Kunming 42
Chennai 41
Guangzhou 41
Tukwila 41
Augusta 40
Denver 40
Shanghai 40
Haiphong 39
Vienna 39
Council Bluffs 38
Da Nang 37
Hebei 37
Tianjin 37
University Park 37
Phoenix 36
Ottawa 35
Belo Horizonte 34
Hangzhou 34
Turku 34
Washington 34
Seoul 33
Stockholm 33
Verona 33
Mexico City 32
Baghdad 30
Manchester 30
Tashkent 29
Totale 18.664
Salva come PNG Salva come JPEG
Nome #
Functional associations between polymorphic regions of the human 3'IgH locus and COVID-19 disease 803
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 527
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR 385
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 269
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 254
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 233
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 231
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 229
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 219
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 218
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 217
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 212
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 210
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 209
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 199
Assessment of neurological manifestations in hospitalized patients with COVID-19 198
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 196
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 195
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 195
Residual respiratory impairment after COVID-19 pneumonia 194
Variability of raltegravir plasma levels in the clinical setting 191
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 190
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 189
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 187
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 186
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 185
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 184
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 183
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 183
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 180
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. 177
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 177
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 177
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 177
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 176
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice 173
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 171
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 170
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 169
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 169
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 167
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 167
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 167
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 166
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 165
Cognitive reserve and neuropsychological functioning in older HIV-infected people 164
Shall we dance? Extending tango's results to clinical practice 163
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 162
Mortality in patients with early- or late-onset candidaemia 161
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 159
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 157
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 156
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 156
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients 156
Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life 155
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 155
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis 155
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 154
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 153
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 153
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 152
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 152
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 152
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice 152
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 151
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 150
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV 150
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 149
Effect of aging and human immunodeficiency virus infection on cognitive abilities 149
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 149
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 148
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 148
HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV 148
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 147
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 147
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 147
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 147
Mortality in patients with early- or late-onset candidaemia 144
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 144
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 144
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 142
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 142
Long term follow-up of Nevirapine-treated patients in a single centre cohort 140
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 140
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 140
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 139
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data 139
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 139
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 139
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 138
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe 138
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 138
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 138
Psychological distress during the initial stage of the COVID-19 pandemic in an italian population living with HIV: An online survey 138
Hospital reengineering against COVID-19 outbreak: 1-month experience of an Italian tertiary care center 138
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 137
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 137
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition 137
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 136
Mortality in patients, with early-or late-onset candidaemia 135
Totale 17.918
Salva come PNG Salva come JPEG
Categoria #
all - tutte 147.579
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 147.579
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202141 0 0 0 0 0 0 0 0 0 0 0 41
2021/20222.197 183 132 44 183 81 65 100 382 81 161 310 475
2022/20235.312 667 752 449 795 475 677 166 404 619 87 160 61
2023/20242.711 105 690 61 318 115 530 129 51 69 82 306 255
2024/20254.989 83 115 471 167 477 199 235 279 734 446 976 807
2025/202613.358 1.947 350 777 1.610 2.295 1.280 2.096 614 801 1.015 443 130
Totale 35.960